Restricted
Coadministration with:
Hypersensitivity to posaconazole, other azole antifungal agents, or any component of the formulation.
Known or suspected hereditary fructose intolerance (delayed-release suspension only).
Laboratory
Clinical
GI upset (~40%)
Headaches
Elevation in hepatic enzymes
Hypersensitivity
Rare but serious effects include QTc prolongation
Posaconazole is an inhibitor and is metabolized by cytochrome P4503A4; therefore, coadministration with other agents that are cytochrome P450 substrates, inducers, or inhibitors will result in significant drug interactions.
You must check for potential drug interactions when initiating Posaconazole therapy or starting a new medication in patients already receiving Posaconazole therapy.
Administration of the following agents with Posaconazole is contraindicated:
Posaconazole inhibits metabolism of the following agents. Dose reductions and close monitoring are recommended when Posaconazole is used with agents concomitantly:
High pharmacokinetic variability, dependent on fatty food administration (for solution).
The two oral formulations of posaconazole (delayed-release tablets and an oral suspension) are not interchangeable, and cannot be directly substituted without a change in dosage.
The delayed-release tablet is generally preferred to the oral suspension because it is easier to administer, better tolerated, and more reliably absorbed.
Antimicrobial class: Azole
Pregnancy category: C
Breastfeeding: It is not known if posaconazole is present in breast milk
Adapted from the UCLA Health Antimicrobial Stewardship Program